Outcomes Following Cytoreduction and HIPEC for Pseudomyxoma Peritonei: 10-Year Experience.
Cytoreductive surgery
Hyperthermic intraperitoneal chemotherapy
Pseudomyxoma peritonei
Journal
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
01
02
2019
accepted:
20
04
2019
pubmed:
16
5
2019
medline:
15
4
2021
entrez:
16
5
2019
Statut:
ppublish
Résumé
Pseudomyxoma peritonei (PMP) is a rare clinical presentation, with considerable morbidity and mortality if left untreated. In recent decades, there is growing acceptance for the use of cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC). The aim of this study was to report on our 10-year single-center experience on outcomes following CRS and HIPEC for PMP of appendiceal origin. A retrospective analysis of a prospectively maintained database of all patients undergoing CRS and HIPEC for PMP of appendiceal origin over a 10-year period at a statewide referral center was conducted. One hundred and seventy-five cytoreductive procedures were undertaken in 140 patients. The mean patient age was 57.4 years, with a female preponderance (56%). The median PCI was 16, with 73.1% of cases having a complete cytoreduction. Grade III/IV complications occurred in 36 (20.6%) cases, with no mortalities. The median overall and disease-free survival was 100 months and 40 months, respectively, with a 71% 5-year survival. High-grade histology was the main factor identified as an independent predictor of worse overall survival. CRS and HIPEC are safe with acceptable rates of morbidity. It can provide very favorable survival in patients with PMP. High-grade histology is a key prognostic factor associated with a worse overall survival.
Sections du résumé
BACKGROUND
Pseudomyxoma peritonei (PMP) is a rare clinical presentation, with considerable morbidity and mortality if left untreated. In recent decades, there is growing acceptance for the use of cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC). The aim of this study was to report on our 10-year single-center experience on outcomes following CRS and HIPEC for PMP of appendiceal origin.
METHODS
A retrospective analysis of a prospectively maintained database of all patients undergoing CRS and HIPEC for PMP of appendiceal origin over a 10-year period at a statewide referral center was conducted.
RESULTS
One hundred and seventy-five cytoreductive procedures were undertaken in 140 patients. The mean patient age was 57.4 years, with a female preponderance (56%). The median PCI was 16, with 73.1% of cases having a complete cytoreduction. Grade III/IV complications occurred in 36 (20.6%) cases, with no mortalities. The median overall and disease-free survival was 100 months and 40 months, respectively, with a 71% 5-year survival. High-grade histology was the main factor identified as an independent predictor of worse overall survival.
CONCLUSION
CRS and HIPEC are safe with acceptable rates of morbidity. It can provide very favorable survival in patients with PMP. High-grade histology is a key prognostic factor associated with a worse overall survival.
Identifiants
pubmed: 31090036
doi: 10.1007/s11605-019-04239-4
pii: 10.1007/s11605-019-04239-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
899-906Références
In Vivo. 2006 Nov-Dec;20(6A):773-6
pubmed: 17203766
Dis Colon Rectum. 2012 Apr;55(4):407-15
pubmed: 22426264
Ann Surg. 2005 Feb;241(2):300-8
pubmed: 15650641
Br J Surg. 2000 Oct;87(10):1414-8
pubmed: 11044169
Dis Colon Rectum. 1987 Oct;30(10):772-9
pubmed: 2820671
J Clin Oncol. 2012 Jul 10;30(20):2449-56
pubmed: 22614976
Eur J Surg Oncol. 2015 Mar;41(3):396-9
pubmed: 25216980
J Clin Pathol. 2012 Oct;65(10):919-23
pubmed: 22718846
Dis Colon Rectum. 2011 Mar;54(3):293-9
pubmed: 21304299
Histopathology. 2017 Dec;71(6):847-858
pubmed: 28746986
Cancer. 1973 Dec;32(6):1525-41
pubmed: 4757938
Am Surg. 2012 Feb;78(2):171-7
pubmed: 22369825
Arch Pathol Lab Med. 2002 Jul;126(7):837-41
pubmed: 12088454
Lancet Oncol. 2012 Aug;13(8):e362-9
pubmed: 22846841
Invest New Drugs. 2012 Oct;30(5):2080-6
pubmed: 22359216
APMIS. 2017 Mar;125(3):207-212
pubmed: 28233447
Ann Surg Oncol. 2016 Dec;23(13):4316-4321
pubmed: 27380645
Langenbecks Arch Surg. 2015 Jan;400(1):37-48
pubmed: 25319432
Eur J Surg Oncol. 2010 May;36(5):456-62
pubmed: 20227231
Br J Surg. 2018 Jan;105(2):e48-e60
pubmed: 29341164
Cancer. 1990 Oct 1;66(7):1636-40
pubmed: 2208015
Eur J Surg Oncol. 2008 Feb;34(2):196-201
pubmed: 17524597
Cancer. 1976 May;37(5):2511-22
pubmed: 1260731
Curr Treat Options Oncol. 2013 Sep;14(3):365-73
pubmed: 23934509
Ann Surg Oncol. 2001 Dec;8(10):787-95
pubmed: 11776492
Dis Colon Rectum. 2017 Apr;60(4):360-367
pubmed: 28267002
Ann Surg. 2011 Apr;253(4):769-73
pubmed: 21475018
Ann Surg Oncol. 2007 Feb;14(2):484-92
pubmed: 17054002
Am J Surg Pathol. 2016 Jan;40(1):14-26
pubmed: 26492181
Lancet Oncol. 2006 Jan;7(1):69-76
pubmed: 16389186
Ann Surg Oncol. 2009 Jul;16(7):1903-11
pubmed: 19387742
World J Gastrointest Surg. 2018 Aug 27;10(5):49-56
pubmed: 30190782
Pathologe. 2012 Feb;33(1):24-30
pubmed: 22179200
Br J Surg. 1998 Oct;85(10):1332-9
pubmed: 9782010
Curr Oncol. 2014 Feb;21(1):e155-65
pubmed: 24523614
Ann Surg. 2007 Jan;245(1):104-9
pubmed: 17197972
Acta Med Austriaca. 1989;16(3-4):57-60
pubmed: 2514551
Cancer Chemother Pharmacol. 1990;25(6):389-94
pubmed: 2311166
Adv Anat Pathol. 2005 Nov;12(6):291-311
pubmed: 16330927
Am J Surg Pathol. 2006 May;30(5):551-9
pubmed: 16699309
Ann Surg. 1994 Feb;219(2):112-9
pubmed: 8129481
Am J Surg Pathol. 1995 Dec;19(12):1390-408
pubmed: 7503361
Eur J Surg Oncol. 2001 Apr;27(3):239-43
pubmed: 11373099
J Surg Oncol. 2008 Sep 15;98(4):277-82
pubmed: 18726894